SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesCognitiveDSIP

DSIP

/ 9-amino-acid peptide isolated from rabbit brain in 1977
TIER 3 · PreclinicalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

ALIAS · Delta Sleep-Inducing Peptide

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequence— sequence not captured —
MW · CLASS · 9-amino-acid peptide isolated from rabbit brain in 1977CATEGORY · Cognitive

Decades of mechanistic investigation since 1977 have not identified a definitive receptor or sleep-promoting mechanism. Human sleep-efficacy evidence is inconclusive.

§ B · Mechanism of action

DSIP is a 9-amino-acid peptide isolated from rabbit brain cerebrospinal fluid during slow-wave sleep. Despite its name, the mechanism by which DSIP might promote sleep in humans remains inconclusive after decades of study.

§ C · Human clinical evidence

Limited human sleep-efficacy studies; results are inconsistent. No definitive mechanism of action established. Not in pharmaceutical development.

§ D · Primary literature
PubMed16805787Kovalzon VM et al.Delta sleep-inducing peptide (DSIP): a still unresolved riddle · Journal of Neurochemistry · reviewReview of delta sleep-inducing peptide (DSIP) clinical and mechanistic literature. Despite decades of investigation since 1977 discovery, the proposed sleep-promoting mechanism is not well established.Limitations: Review; no definitive receptor or mechanism identified. Human sleep-efficacy data remains inconclusive.2006
§ F · Safety signal

Generally reported as well-tolerated in the limited published human studies. No long-term safety data at doses commonly sold in the research-chemical market.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

The 1977 name "delta sleep-inducing peptide" reflects the conditions of discovery rather than a proven pharmacological property. Marketing claims about sleep benefits outrun the available human evidence.